最新医学別冊 新しい診断と治療のABC36/血液4 急性白血病 改訂第2版

出版社: 最新医学社
発行日: 2012-08-25
分野: 臨床医学:一般  >  雑誌
ISSN: 03708241
雑誌名:
特集: 急性白血病 改訂第2版
電子書籍版: 2012-08-25 (改訂第2版)
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

5,500 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

4,400 円(税込)

目次

  • 最新医学別冊 新しい診断と治療のABC36/血液4 急性白血病 改訂第2版

    ―目次―

    特集 急性白血病 改訂第2版

    第1章 概念・分類と疫学
     概念と分類  
     疫学  

    第2章 病因
     染色体異常  
     遺伝子異常と病因  

    第3章 診断
     診断,検査所見,鑑別診断  
     一般内科医や開業医が初期の白血病を見逃さないためのポイント

    第4章 管理・治療
     急性白血病に使用される薬物  
     急性骨髄性白血病の治療  
     急性前骨髄球性白血病の治療  
     成人急性リンパ性白血病の治療  
     思春期・若年成人急性リンパ性白血病の治療 
     小児急性リンパ性白血病の治療 
     フィラデルフィア染色体陽性急性リンパ性白血病の治療  
     高齢者急性白血病の治療  
     進行期骨髄異形成症候群の治療  
     急性白血病の造血幹細胞移植療法 
     成人T細胞性白血病の治療 
     中枢神経白血病・髄外白血病の予防と治療 
     急性白血病治療時の感染症対策 
     急性白血病治療時の顆粒球コロニー刺激因子の使い方 
     急性白血病治療時の出血対策 
     急性白血病治癒患者における晩期後遺症  
     急性白血病の治療効果判定方法とMRD(微小残存白血病) 

    第5章 治療ガイドライン
     第1寛解期急性白血病に対する
      寛解後療法としての化学療法と移植の治療選択

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

第1章 概念・分類と疫学

P.22 掲載の参考文献
1) 日本血液学会編:日本血液学全書. 丸善, 東泉, 1962.
2) 勝沼精蔵:血液疾患の診断及び療法白血球方面, 第32回日本内科学会総会宿題報告 (名古屋大学医学部図書館蔵), 1935.
3) 山田一正編:急性白血病. 内科MOOK, 金原出版東京, 1978
7) Tumors of hematopoietic and lymphoid tissues (Jaffe E S, et al, eds). International Agency for research on cancer, Lyon, 2001.
8) WHO classification of Tumors of hematopoietic and lymphoid tissues (Swerdlow S H, et al, eds). International Agency for research on cancer, Lyon, 2008.
9) Dameshek W:Some speculations on the myeloproliferative syndromes. Blood 6:372-375, 1951.
P.33 掲載の参考文献
1) 厚生労働省大臣官房統計情報部編:国際疾病分類-腫瘍学 第3版. 厚生統計協会, 2003.
2) Jaffe E S, et al:Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues. IARC press, Lyon, 2003.
3) Swerdlow, et al:WHO Classification of Tumours of Haematopoietic and Lymphoid Tissue. IARC press, Lyon, 2008.
5) Ferlay J, et al:GLOBOCAN 2008 v1. 2, Cancer Incidence and Mortality Worldwide:IARC Cancer Base No.10 [nternet]. Lyon, France:International Agency for Research on Cancer;2010. Available from:(http://globocan.iarc.fr, accessed on day/month/year.)
7) United Nations Scientific Committee on the Effects of Atomic Radiation:Sources and effects of ionizing radiation. UNSCEAR 2000 Reprt to the General Assembly with Scientific Annexes, volume II:Effects. New Yourk, United Nations Publications, 2000.
12) Angelillo I F, et al:Residential exposure to electromagnetic fields and childhood leukaemia:a meta-analysis. Bull World Health Org 77:906-915, 1999.
14) International Agency for Research on Cancer:Overall Evaluations of Carcinogenecity:An Updating of IARC Monographs Vols. 1 to 42, supplement 7. IARC Press, Lyon, 1987.
15) Boice J D, et al:Cancer Mortality in women after repeated fluoroscopic examinations of the chest. J Natl Cancer Inst 66:863-867, 1981.

第2章 病因

P.42 掲載の参考文献
1) 50th Anniversary of the Discovery of the Philadelphia Chromosome http://pubweb.fccc.edu/philadelphiachromosome/
2) Nowell P C, et al:A minute chromosome in human chronic granulocytic leukemia. Science 132:1497, 1960
4) Rowley J D:Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 16:109-112, 1973.
5) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (ed 4). IARC 10, Lyon, France, 2008.
7) Romana SP, et al:The t (12;21) of acute lymphoblastic leukemia results in a tel-AMLI gene fusion. Blood 85:3662-3670, 1995.
9) Shiba N, et al:NUP98-NSDI fusion gene is strongly associated with a poor prognosis in pediatric acute myeloid leukemia:a study of the Japanese Childhood AML99 Cooperative Study Group. ASH Annual Meeting Abstracts 118:1475, 2011.
10) Ichikawa H, et al:An RNA-binding protein gene, TLS/FUS, is fused to ERG in human myeloid Ieukemia with t (16;21) chromosomal translocation. Cancer Res 54:2865-2868, 1994.
11) Gamou T, et al:The partner gene of AMLl in t(16;21) myeloid malignancies is a novel member of the MTG8 (ETO) family. Blood 91:4028-4037, 1998.
13) 阿部達生編, 第3章分子遺伝学の手技と遺伝子異常の解析. 3-a 分子生物学的診断技術. 3-b FISH法. 造血器腫瘍アトラス. p60-107. 日本医事新報社, 2009.
14) Shaffer L G, et al:ISCN:An International System of Human Cytogenetic Nomenclature, Karger, Basel, 2009.
P.55 掲載の参考文献
9) Becker H, et al:Favorable prognostic impact of NPMI mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene-and micro RNA-expression signatures:a Cancer and Leukemia Group B study. J Clin Oncol 28 (4):596-604, 2010.
13) Figueroa M E, et al:Leukemic IDHI and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 18 (6):553-567, 2010.
18) Ahuja H G, et al:The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood 75 (8):1684-1690, 1990.
19) Paschka P, et al:Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv (16) and t (8;21):a Cancer and Leukemia Group B Study. J Clin Oncol 24 (24):3904-3911, 2006.

第3章 診断

P.64 掲載の参考文献
2) Jaffe E S et al:WHO classification. Tumours of haematopoietic and lymphoid tissues. IARC press, Lyon, 2001.
3) Swerdlow S H, et al:WHO classification. Tumours of haematopoietic and lymphoid tissues 4th e (1. IARC press, Lyon, 2008
5) Kralovics R et al:Again-of-function mutation of JAK2 in myeloproliferative disorders. N Engl JMed 352:1729-1790, 2005.
7) 朝長万左男, 他編:不応性貧血 (骨髄異形成症候群) の形態学的異形成に基づく診断確度区分と形態診断アトラス, 厚生労働科学研究費補助金 難治性疾患克服研究事業 特発性造血障害に関する調査研究班, 2008

第4章 管理・治療

P.81 掲載の参考文献
1) Plunkett W, et al:Saturation of 1-B-D-arabinofuranosylcytosine 5'-triphosphate accumulation in leukemia cells during high-dose 1-B-D-arabinofuranosylcytosine therapy. Cancer Res 47:3005-3011, 1987.
2) Yamauchi T, et al:A new sensitive method for determination of intracellular 1-beta-D-arabinofuranosylcytosine 5Ltriphosphate content in human materials in vivo. Cancer Res 56:1800-1804, 1996.
3) Gandhi V, et al:Cellular and clinical pharmacology of fludarabine. Clin Pharmacokinet 41:93-103, 2001.
5) Yamauchi T, et al:DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine. Clin Cancer Res 7:3580-3589, 2001.
6) o'Brien S M, et al:Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420, 2001.
10) Braham J, et al:Effect of methotrexate on intracellular folate pools in purified myeloid precursor cells from normal human bone marrow. J Clin Invest 79:692-697, 1987.
11) Tew K D, et al:Alkylating agents, In:Cancer Chemotherapy and biotherapy, 3rd ed (Chabner B A, et al, eds), p373-414. Lippin-cott-Raven Publishers, Philadelphia, 2001.
13) Chabner B A, et al:Enzyme therapy:L-As-paraginase, In:Cancer Chemotherapy and biotherapy, 3rd ed (Chabner B A, et al, eds), p647-656. Lippincott-Raven Publishers, Philadelphia, 2001.
14) Tallmann M S:Curative therapeutic approaches to APL. Ann Hematol 83 (Suppl 1):S81-S82, 2004.
16) Petersdorf S, et al:Preliminary results of Southwest Oncology Group Study SO106:an international intergroup Phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy fbllowed by a second randomization to post-consolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia. Blood 114:790, 2009.
P.93 掲載の参考文献
4) Bishop JF, et al:Etoposide in acute nonlymphocytic leukemia. Australian Leukemia Study Group. Blood 75 (1):27-32, 1990.
5) Bishop J F, et al:A randomized study of high-dose cytarabine in induction in acute myeloid leukemia. Blood 87 (5):1710-1717, 1996.
6) Weick J K, et al:A randomized investigation of high-dose versus standard-dose cyosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia:a Southwest Oncology Group study. Blood 88 (8):2841-2851, 1996.
7) Bloomfield C D, et al:Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 58 (18):4173-4179, 1998.
10) Grimwade D, et al:Refinement of cytogenetic classification in acute myeloidleukemia:determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116 (3):354-365, 2010.
11) Kuriyama K, et al:Scoring systems for predicting prognoses of the patients with AML treated according to the Japan Adult Leukemia Study Group (JALSG) protocols. Rinsho Ketsueki 39 (2):98-102, 1998.
13) Koreth J, et al:Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission:systematic reviewand meta-analysis of prospective clinical trials. JAMA 301 (22):2349-2361, 2009.
P.103 掲載の参考文献
2) Avvisati G, et al:Induction therapy with idarubicin alone siginificantly influences evevt-free survuvual duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia:final results of the GIMEMA randomized study LAP0839 with 7years of minimal follow-up. Blood 100 (9):3141-3146, 2002.
3) Mandelli F, et al:Molecular remission in PML/RAR a-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90 (3):1014-1021, 1997
4) Sanz M A, et al:A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic ethcacy and reduced toxicity in newly diagnosed PML/ RARa-positive acute promyelocytic leukemia. Blood 94 (9):3015-3021, 1999.
5) Fenaux P, et al:A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 94 (4):1192-1200, 1999.
6) Burnett A K, et al:Presenting white cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with All-rans retinoic acid:Results of the randomized MRC trial. Blood 93 (12):4131-4143, 1999.
7) Ades A, et al:Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Group. J Clin Oncol 24 (36):5703-5710, 2006
9) Sanz M A, et al:Risk-adopted treatment of acute promyelocytic leukemia with alltrans retinoic acid and anthracycline monochemotherapy:amulticenter study by the PETHEMA group. Blood 103 (4):1237-1243, 2004.
13) Asou N, et al:Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia:the APL92 study of the Japan aduly Leukemia Study Group (JALSG). Cancer Chemother Pharmacol 48 (suppl 1):S65-71, 2001.
16) Mathews V, et al:Singlagent arsenic trioxide in the treatment of newly diagnosed aute promyelocytic leukemia:long-term follow-up data. J Clin Oncol 28 (24):3866-3871, 2010.
21) Aribi A, et al:Combination therapy with arsenic trioxide, all-trans retinoic acid and gemtuzumabozogamicin in recurrent acute promyelocytic leukemia. Cancer 109 (7):1355-1359, 2007.
25) Mandelli F, et al:Treatment of elderly patients (≧60 years) with newly diagnosed acute promyelocytic leukemia. Results of Italian multicenter group GIMEMA with ATRA and idarubicin (AIDA) protocols. Leukemia 17 (6):1085-1090, 2003.
P.112 掲載の参考文献
1) Ribera J M, et al:Comparison of intensive chemotherapy, allogeneic or autologous Stem Cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90 (10):1346-1356, 2005.
6) Thomas X, et al:Outcome of treatment in adults with acute lymphoblastic leukemia:analysis of the LALA-94 trial. J Clin Oncol 22 (20):4075-4086, 2004.
11) Huguet F, et al:Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia:the GRAALL-2003 study. J C lin Oncol 27(6):911-918, 2009.
23) Larson R A, et al:A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia:CALGB study 9111. Blood 92 (5):1556-1564, 1998.
P.124 掲載の参考文献
4) Ribera J M, et al:Comparison of the results of the treatment of adolescents and young dults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatricbased protocol ALL-96. J Clin Oncol 26:1843-1849, 2008.
5)Huguet F, et al:Pediatric-inspired therapyin adults with Philadelphia chromosome negative acute lymphoblastic leukemia:the GRAALL-2003 study. J Clin Oncol 27:911-918, 2009.
P.132 掲載の参考文献
3) Hasegawa D, et al:Successful Abolition of Prophylactic Cranial Irradiation in Children with Non-T Acute Lymphoblastic Leukemia (ALL) in the Japan Association of Childhood Leukemia Study (JACLS) ALL-02 Trial. Blood (ASH Annual Meeting Abstracts) 118:Abstract 1506, 2011.
9) Mullighan C G, et al:Genome-wide analysisof genetic alterations in acute ltmphoblastic leukemia. Nature 446:758-764, 2007.
11) Conter V, et al:Molecular response totreatment redefines all prognostic factors inchildren and adolescents with B-cell precursor acute lymphoblastic leukemia:results in 3184 patients of the AIEOP-BFMALL 2000 study. Blood 115:3206-3214, 2010.
17) Schultz K R, et al:Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:A Children's Oncology Group Study. J Clin Oncol 27:5175-5181, 2009.
P.144 掲載の参考文献
4) Gleissner B, et al:Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia:aprospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood 99:1536-1543, 2002.
6) Barrett A J, et al:Bone marrow transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 79:3067-3070, 1992.
12) Yanada M, et al:High complete remissionrate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABIx・positive acute lymphoblastic leukemia:a phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol 24:460-466, 2006.
14) Ribera J M, et al:Concurrent intensivechemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acutelymphoblastic leukemia. Final results ofthe CSTIBES02 trial. Haematologica 95:87-95, 2010.
17) Vignetti M, et al:Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelphia chromo-some-positive patients with acute lymphoblastic leukemia without additional chemotherapy:results of the Gruppo Italiano Malattie Ematologiche dell:Adulto (GIMEMA) LAL0201-B protocol. Blood 109:3676-3678, 2007.
20) Hatta Y, et al:Promising Outcome of Imatinib-Combined Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia:Results of the Japan Adult Leukemia Study Group (JALSG) Ph+ALL202 Regimen. Blood (ASH Annual Meeting Abstracts) 114:3090, 2009.
24) Fob R, et al:Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood 118:6521-6528, 2011.
25) Jabbour E, et al:Combination of the hyper-CVAD Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Meyloid Leukemia (CML-LB). Blood (ASH Annual Meeting Abstracts) 112:Abstract 2919, 2008.
26) Quinta's-Cardama A, et al:Tyrosine kinase inhibitor-induced platelet dysfunction inpatients with chronic myeloid leukemia. Blood 114:261-263, 2009.
29) Cimino G, et al:The role of BCR/ABL iso-forms in the presentation and outcome ofpatients with Philadelphia-positive acutelymphoblastic leukemia:a seven-year update of the GIMEMA 0496 trial. Haematologica 91:377-380, 2006.
31) Martinelli G, et al:IKZF1 (lkaros) Deletions in BCR-ABL1-Positive Acute Lymphoblastic Leukemia Are Associated With Short Disease-Free Survival and High Rate of Cumulative Incidence of Relapse:A GIMEMA AL WP Report. J Clin Oncol 27:5202-5207, 2009.
32) Topp M S, et al:Anti-CD19 BiTE Blinatumomab Induces High Complete Remission Rate In Adult Patients with Relapsed B-Precursor ALL:Updated Results of An On-going Phase H Trial. Blood (ASH Annual Meeting Abstracts) 118:Abstract 252, 2011.
P.153 掲載の参考文献
1) Miyawaki S et al, A randomized comparisons of 4 courses of standard-dose multiagent chemotherapy versus 3 courses ofhigh-dose cytarabine alone in postremission therapy for acute myeloid leukemia inadults:the JALSG AML201 Study. Blood 117 (8):2366-2372, 2011.
4) Wakita A, et al:Randomized comparison offixed-schedule versus response-oriented individualized induction therapy and use of Ubenimex during and after consolidation therapy for elderly patients with acute myeloid leukemia:the JALSG GML200 study. Int J Hematol, (in press)
8) Lowenberg B, et al High-dose daunorubicin in older patients with acute myeloidleukemia. N Engl J Med 361 (13):1235-1248, 2009.
14) Burnett A K, et al:Identification of patientswith acute myeloblastic leukemia who benet from the addition of gemtuzumab ozogamicin:results of the MRC AML15 trial. J Clin Oncol 29 (4):369-377, 2011.
P.161 掲載の参考文献
1) Greenberg P, et al:International scoring system for evaluating Prognosis in myelodysplastic syndromes. Blood 89:2079-2088, 1997.
4) Palumbo A, et al:Continuous Lenalidomide Treatment for Newly Diagnosed Multiple Myeloma N Engl J Med 336:1759-1769, 2012.
5) レブラミド. カプセル5mg安全性情報のお知らせ. 2011年4月, セルジーン株式会社.
6) Silverman L R, et al:Randomized controlled trial of azacytidine in patients with the myelodysplastic syndrome:astudy of the cancer and leukemia group B. J Clin Oncol 20:2429-2440, 2002.
7) Fenaux P, et al:Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes:a randomised, open-labeled, phase III study. Lancet Oncol 10:223-232, 2008.
9) Seymour J F, et al:Effects of azacitidine compared with conventional care regimens in elderly (≧75 years) patients with higherrisk myelodysplastic syndromes. Crit Rev Oncol Hematol 76:218-227, 2010.
P.171 掲載の参考文献
2) Kuwatsuka Y, et al:Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia:t(8;21) and inv (16) represent different clinical outcomes. Blood 113 (9):2096-2103, 2009.
9) Thomas X, et al:Outcome of treatment in adults with acute lymphoblastic leukemia:analysis of the LALA-94 trial. J Clin Oncol 22 (20):4075-4086, 2004.
12) Stem Cell Trialists:Collaborative Group:Allogeneic peripheral blood stem cell compared with bone marrow transplantation in the management hematologic malignancies:an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 19 (16):5074-5087, 2005.
17) Bensinger W:Individual patient data meta-analysis of allogeneic peripheral blood stemcell transplant vs bone marrow transplant in the management of hematological malignancies:indirect assessment of the effect of day 11 methotrexate administration. Bone Marrow Transplant 38 (8):539-546, 2006.
P.181 掲載の参考文献
1) Uchiyama T, et al:Adult T-cell leukemia:clinical and hematologic features of 16 cases. Blood 50:481-492, 1977.
4) Yamada Y, et al:Nationwide survey of adult T-cell leukemia/lymphoma (ATL) in Japan. Rinsho Ketsueki 52:1765-1771, 2011.
6) Ishida T, et al:Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma:its close association with skin involvement and unfavorable outcome. Clin Cancer Res 9:3625-3634, 2003.
P.189 掲載の参考文献
3) Thomas X, et al:Outcome of treatment in adults with acute lymphoblastic leukemia:analysis of the LALA-94 trial J Clin Oncol 22 (20):4075-4086, 2004.
7) Cortes J, et al:The value of high-dose systemic chemotherapy and intrathecal therapy for central nervous system prophylaxis in different risk groups of adult acute lymphoblastic leukemia. Blood 86 (6):2091-2097, 1995.
9) 齋藤宏文, 他:ダサチニブの髄液移行の検討:Ph陽性白血病に対するCNS白血病発症予防の可能性. 臨血 50 (9):920, 2009.
P.203 掲載の参考文献
4) 秋山暢, 他:JALSG AML201試験における急性骨髄性白血病の感染症に関する解析と感染症起因菌の年次推移, 感染症誌 85:600, 2011.
5) 秋山暢:4. 発熱性好中球減少症の臨床検査. 発熱性好中球減少症の予防と対策 (田村和夫編) p82-96. 医薬ジャーナル社, 大阪2010.
8) Leivovici L, et al:Antibiotic prophylaxis in neutropenic patients:new evidence, practical decisions. Cancer 107:1743, 2006.
9) Imran H, et al:Fluoroquinolone prophylaxis in patients with neutropenia:ameta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 27:53-63, 2008.
14) Vehreshild J J, et al:Effficacy of caspofungin and itraconazole as secondary antifungal prophylaxis:analysis of data from a multinational case registry. Int J Antimicrob Agent 34:446-450, 2009.
16) 中川靖章, 他:血液疾患におけるFebrile neutropenia (FN) ガイドライン実証的研究 (II). 感染症誌 82:716, 2008.
18) Akiyama N, et al:Efficacy and safety ofdoripenem for sepsis with neutropenia in Japanese patients with hematologic diseases. Jpn J Antibiot (in press)
19) Pagano L, et al:The use and efficacy of empirical versus pre-emptive therapy in the management of fullgal infections:the HEMA e-Chart Project. Haematologica 96:1366-1370, 2011.
20) Walsh T J, et al:Caspofungin versus liposo mal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 351:1391-1402, 2004.
23) Boogaets M, et al:Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical anti-fungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibiotics. Ann Intern Med 135:412-422, 2001.
25) Papas P G, et al:Clinical practice guidelines for the management of candidiasis:2009 update by the Infectious Disease Society of America. Clin Infect Dis 48:503-535, 2004.
26) Gilbert D N, et al:The Sanford Guide to antimicrobial therapy 2012. 42nd edition. p 125. Antimicrobial Therapy, Inc. Sperryville, VA, USA, 2012.
27) Walsh T J, et al:Treatment of aspergillosis:clinical practice guidelines of the Infectious Disease Society of America Clin Infect Dis 46:327-360, 2008.
31) Maertens J, et al:Efficacy and Safety of Caspofungin for Treatment of Invasive As-pergillosis in Patients Refractory to or Intolerant of Conventional Antifungal Therapy. Clin Infect Dis 39:1563-1571, 2004.
35) Suzuki K, et al:Fatal Trichosporon fungemia in patients with hematologic malignancies. Eur J Haematol 84:441-447, 2009.
36) Bayamogle G, et al:Breakthrough Trichosporon asahii fungemia in neutropenic patient with acute leukemia while receiving caspofungin. Infection 36:68-70, 2008.
38)時松一成:今後留意すべき感染症6.深在性トリコスポロン症.化療の領域 26:234-239,2010.
P.215 掲載の参考文献
1) AViles A, et al:Results of a randomized trial of granulocyte colony-stimulating factor in patients with infection and severe granulo-cytopenia. Anticancer Drugs 7 (4):392-397, 1996.
2) Smith T J, et al:2006 update of recommen-dations for the use of white blood cell growth factors:an evidence-based clinical practice guideline. J Clin Oncol 24 (19):3187-3205, 2006.
4) Heil G, et al:Long-term survival data from aphase 3 study of Filgrastim as an adjunct to chemotherapy in adults with de novo acute myeloid leukemia. Leukemia 20 (3):404-409, 2006.
5) Usuki K, et al:Efficacy of granulocyte colony-stimulating factor in the treatment of acute myelogenous leukaemia a multi-centre randomized study. Br J Haematol 116 (1):103-112, 2002.
9) von Lilienfeld-Toal M, et al:A randomized comparison of immediate versus delayedapplication of G-CSF in induction therapyfor patients with acute myeloid leukemia unfit for intensive chemotherapy. Haematologica 92 (12):1719-1720, 2007.
10) Ohno R, et al:A double-blind controlled study of granulocyte colony-stimulatingfactor started two days before induction chemotherapy in refractory acute myeloid leukemia Kohseisho Leukemia Study Group. Blood 83:2086-2092, 1994.
11) Lowenberg B, et al:Effect of priming with granulocyte colony-stimulating factor onthe outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 349:743-752, 2003.
13) Ottmann O G, et al:Concomitant granulocyte colony-stimulating factor and induction chemoradiotherapy in adult acute lymphoblastic leukemia:a randomized phase III trial. Blood 86:444-450, 1995.
14) Larson R A, et al:A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy foradults with acute lymphoblastic leukemia:CALGB study 9111. Blood 92:1556-1564, 1998.
17) Ringden O, et al:Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death:a study from the acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 22 (3):416-423, 2004.
P.230 掲載の参考文献
1) 平成11年6月10日医薬発第715号 厚生省医薬安全局長 通知「血液製剤の使用指針」;1999.
2) 平成6年7月11日厚生省薬務局長通知, 薬発第638号:1994.
4) Rebulla P, et al:The threshold for prophy-lactic platelet transfusions in adults with acute myeloid leukemia. Gruppo Italiano Malattie Ematologiche Maligne dell' Adulto. N Engl J Med 337:1870-1875, 1997.
7) 各都道府県知事あて厚生労働省医薬食品局長通知:血小板製剤の使用適正化の推進及び「輸血療法の実施に関する指針」の一部改正について. 平成16年9月17日付薬食発第0917005号;2004.
8) 白血球除去フィルター使用の輸血時における血圧低下, ショックについて. 厚生労働省医薬品等安全性情報Vol 150, 1998
10) Drake T A, et al:Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. Am J Pathol 134:1087-1097, 1989.
15) 中川雅夫:本邦における播種性血管内凝固 (DIC) の発症頻度・原因疾患に関する調査報告. 厚生省特定疾患血液系疾患調査研究班血液凝固異常症分科会 平成10年度研究業績報告書 57-64, 1999.
16) Wada H, et al:Outcome of disseminated intravascular coagulation in relation to the score when treatment was begun. Mie DIC Study Group. Thromb Haemost 74:848-852, 1995.
18) Saito H, et al:Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation:results of phase HI randomized double-blind clinical trial. J Thromb Haemost 5:31, 2007.
P.239 掲載の参考文献
3) 石田也寸志:小児がん経験者の長期フォローアップ. 日小血液会誌 22:144-155, 2008.
5) 大園秀一, 他:小児がん長期フォローアップ調査報告. 日小会誌 111:1392-1398, 2007.
6) 石田也寸志:北米Childhood Cancer Survivor Studyによる小児がん経験者の長期的な問題点-第1編. 日小会誌 110:1513-1522, 2006.
7) 石田也寸志:北米Childhood Cancer Survivor Studyによる小児がん経験者の長期的な問題点-第2編. 日小会誌 110:1523-1533, 2006.
12) 石田也寸志, 他:小児がん経験者の晩期合併症およびQOLの実態に関する横断的調査研究第1報. 日小会誌 114:665-675, 2010.
13) 石田也寸志, 他:小児がん経験者の晩期合併症およびQOLの実態に関する横断的調査研究第2報. 日小会誌 114:676-686, 2010.
14) 石田也寸志, 他:小児がん経験者の横断的調査研究における自由記載欄の解析. 日小会誌 116:526-536, 2012.
17) Armenian S H, et al:Long-term health-related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy:areport from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood 118:1413-1420, 2011.
21) 加藤剛二:造血細胞移植後の予防接種. 血腫瘍 54:286-293, 2007.
P.250 掲載の参考文献
3) Kronke J, et al:Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia:a study from the German-Austrian Acute Myeloid Leukemia Study Group. J Clin Oncol 29 (19):2709-2716, 2011.
6) Corbacioglu A, et al:Prognostic impact of minimal residual disease in CBFB-MYHII positive acute myeloid leukemia. J Clin Oncol 28 (23):3724-3729, 2010.
11) Cilloni D, et al:Realtime quantitative polymerase chain reaction detection of minimal residual disease by standerised WTI assay to enhance risk stratification in acute myeloid leukemia:a European Leukemia Net study. J Clin Oncol 27 (31):5195-5201, 2009.
12) Voscoba D, et al:Stability of leukemia associated aberrant immunophenotypes in patients with acute leukemia between diagnosis and relapse:comparison with cytomorphologic, cytogenetic and moleculargetetic findings. Cytometry B Clin Cytom 62 (1):25-38, 2004.
13) Rubnitz J E, et al:Minimal residual diseasedirected therapy for childhood acute myeloid leukemia results of AML02 multicenter trial. Lancet Oncol 11 (6):543-552, 201.
14) Diverio D, et al:Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARa fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter"AIDA" trial. Blood 92 (3):784-789, 1998.
16) Al-Mawali A, et al:The use of receiver operating characteristics analysis for detection of minimal residual disease using fie-color multiparameter flow cytometry in acute myeloid leukemia identifies patients with high risk of relapse. Cytometry B CLin Cytom 76 (2):91-101, 2009.
18) Bruggermann M, et al:Standardized MRD quantification in European ALL trial:proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008. Leukemia 24:521-535, 2010.

第5章 ガイドライン

P.267 掲載の参考文献
1) Kako S, et al:Adecision analysis of allogeneic hematopoietic stem cell transplantation in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission who have an HLA-matched sibling donor. Leukemia 25:259-265, 2011.
3) Slovak M L, et al:Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia:a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 96:4075-4083, 2000.
4) Grimwade D, et al:The importance of diagnostic cytogenetics on outcome in AML:analysis of 1,612 patients entered into the MRC AML IO trial The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 92:2322-2333, 1998.
7) Zittoun R A, et al:Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell:Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 332:217-223, 1995.
8) Cassileth P A, et al:Chemotherapy compared with autologous or allogeneic bonemarrow transplantation in the management of acute myeloid leukemia in first remission. N Engl J Med 339:1649-1656, 1998.
12) Cornelissen J J, et al:Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stemcell transplantation in first remission acute myeloid leukemia in young and middle aged adults:benefits for whom? Blood 109:3658-3666, 2007.
13) Koreth J, et al:Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission:systematic reviewand meta-analysis of prospective clinical trials. JAMA 301:2349-2361, 2009.
20) Ribera J M, et al:Comparison of intensive chemotherapy, allogeneic or autologous stem Cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica 90:1346-1356, 2005.
23) Thomas X, et al:Outcome of treatment in adults with acute lymphoblastic leukemia:analysis of the LALA-94 trial, J Clin Oncol 22:4075-4086, 2004.
25) Attal M, et al:Consolidation treatment of adult acute lymphoblastic leukemia:a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood 86:1619-1628, 1995.
26) Labar B, et al:Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin's lymphoma for patients <or=50 years old in first complete remission:results of the EORTC ALL-3 trial. Haematologica 89:809-817, 2004.

最近チェックした商品履歴

Loading...